Doctors may have found the best way to keep lung cancer patients from dying

BALTIMORE — In a world where cancer remains a formidable foe, a glimmer of hope has emerged for those battling non-small cell lung cancer. A recent analysis by researchers at the Johns Hopkins Kimmel Cancer Center has unveiled a potential paradigm shift in treatment strategies that could significantly improve patients’ chances of survival.

The study, which will be presented at the International Association for the Study of Lung Cancer 2024 World Conference in San Diego, suggests that patients may benefit substantially from receiving immunotherapy treatments both before and after surgery, rather than just before.

“There’s been a big migration in lung cancer and in melanoma treatment in the last few years from doing surgery upfront and giving postoperative immunotherapy, to giving immunotherapy prior to surgery. But our analysis in individual patients in these two trials suggests that there is likely a further benefit from receiving additional immunotherapy treatment after surgery,” explains Dr. Patrick Forde, an adjunct professor of oncology at the Johns Hopkins University School of Medicine, in a media release.

This revelation comes at a time when the medical community has been increasingly focused on harnessing the power of the body’s immune system to fight cancer. Immunotherapy, a treatment that helps the immune system recognize and attack cancer cells, has shown promising results in various types of cancer, including lung cancer.

The researchers compared two groups of patients: one that received immunotherapy only before surgery, and another that received it both before and after. Patients who received at least one dose of the immunotherapy drug nivolumab after surgery showed a 40% reduction in the risk of their cancer coming back or death.

What does this mean for patients?

Imagine your immune system as a highly trained army. Immunotherapy before surgery is like sending in a special forces team to weaken the enemy’s defenses. Adding immunotherapy after surgery is like deploying reinforcements to mop up any remaining resistance and prevent the enemy from regrouping.

Interestingly, the benefits of this extended immunotherapy approach were seen across different patient groups. Whether patients had early or advanced stages of cancer, they showed similar improvements. Even more intriguing was the observation that patients whose tumors had lower levels of a protein called PD-L1 – which usually helps cancer cells evade the immune system – seemed to benefit more from the extended treatment.

This finding challenges the conventional wisdom that patients with lower PD-L1 levels might not respond as well to immunotherapy. It suggests that even patients who were previously thought to be less ideal candidates for immunotherapy could potentially benefit from this approach.

Moreover, the extended immunotherapy regimen proved beneficial even for patients who didn’t achieve a complete response to the initial treatment before surgery. This offers hope to a broader range of patients, including those who might not have seen optimal results from pre-surgical treatment alone.

For patients facing the daunting prospect of lung cancer surgery, this study offers a ray of hope – a possibility that their own immune system, with a little extra help, could be the key to a cancer-free future.